2023 Grant Cycle
Thank you for your interest in applying for a mesothelioma research grant from the Mesothelioma Applied Research Foundation for the 2023 grant cycle. Our research grant program offers $100,000 grants for two years ($50,000 per year).
- The pre-application LOI (Letter of Intent) submission period opens Wednesday, September 27.
- The LOI deadline is at 11:59 PM ET on Friday, November 17, 2023.
Who Can Apply:
- Investigators who have a doctoral-level degree and a full-time faculty position or equivalent at a college, university, medical school, or eligible not-for-profit research organization globally.
- Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.
Additional information to be included in the LOI:
- All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2023 Areas of Interest (listed below).
- All projects must be feasible within the timeline and budgetary constraints of the current LOI.
- All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.
Areas of Interest 2023 (not listed in order of priority):
- Novel therapies for mesothelioma for both pleural and peritoneal, especially targeted therapies, combination immunotherapy, cellular therapy, and virotherapy.
- Health-related quality of life assessment incorporating the social determinants of health (SDOH) specific to mesothelioma patient care, side effect management, mental health care impact on patient and/or caregiver outcomes, and other related topics.
- Novel strategies for screening and early detection.
- Novel strategies for risk assessment and prognosis stratification.
- Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection, and management).
- Improving personalization of therapies (gender and racial differences, targeted therapies, and predictive biomarkers).
- Mechanisms of treatment resistance/failure.
- Mesothelioma biology and etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment).
For questions, please contact Nicole Yost at [email protected] or 703-879-3797.
